SCHEMBL5320462

SCHEMBL5320462

CN(CCO)CCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31647844 0.89 DUT (0.33)
SCHEMBL1671907 0.82
SCHEMBL27383371 0.82
SCHEMBL26645159 0.82 HTR1D (0.33)
SCHEMBL16590610 0.81 MAPT (0.46) LMNAMAPT
SCHEMBL22762098 0.81
SCHEMBL24614980 0.79 MEN1 (0.39) MEN1KMT2A
SCHEMBL20660276 0.78 SIGMAR1 (0.40)
SCHEMBL20660409 0.78 DRD2 (0.32)
SCHEMBL31294926 0.77 DUT (0.33) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2023-07-27 US disclosed
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2023-07-27 US disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 EP disclosed
US-11578090-B2 Nucleic acid-polypeptide compositions and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2023-02-14 US disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 US disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 EP disclosed
US-20200385414-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2020-12-10 US disclosed
WO-2020247782-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-12-10 WO disclosed
US-8197758-B2 Bodipy fluorophore dyes useful in the labeling and identification of proteins; highly soluble MONTANA STATE UNIVERSITY (US) 2012-06-12 US disclosed
US-7833799-B2 Zwitterionic dyes for labeling in proteomic and other biological analyses MONTANA STATE UNIVERSITY (US) 2010-11-16 US disclosed
US-20100203645-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANAYLSES NATIONAL SCIENCE FOUNDATION 2010-08-12 US disclosed
US-20100036133-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES MONTANA STATE UNIVERSITY (US) 2010-02-11 US disclosed
US-7582260-B2 Zwitterionic dyes for labeling in proteomic and other biological analyses MONTANA STATE UNIVERSITY (US) 2009-09-01 US disclosed
US-20090137597-A1 Novel quinoxalinone derivatives MSD K.K. (JP) 2009-05-28 US disclosed
US-7388010-B2 Quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-17 US disclosed
US-20070259333-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES MONTANA STATE UNIVERSITY (US) 2007-11-08 US disclosed
US-20070259333-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES MONTANA STATE UNIVERSITY (US) 2007-11-08 US disclosed
WO-2007102679-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME JE IL PHARMACEUTICAL CO., LTD. (KR) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS LMNA 2991/4885ALDH1A1 3370/4885KDM4E 3689/4885
US-20200385414-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF POLM, POLN, POLI LMNA 269/4885ALDH1A1 4367/4885KDM4E 4639/4885
US-20090137597-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB7 LMNA 976/4885ALDH1A1 975/4885KDM4E 2867/4885
US-11578090-B2 Nucleic acid-polypeptide compositions and uses thereof POLM, POLN, POLI LMNA 269/4885ALDH1A1 4367/4885KDM4E 4639/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS LMNA 2991/4885ALDH1A1 3370/4885KDM4E 3689/4885
US-20100203645-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANAYLSES ACP1, ANXA5, CHAMP1 LMNA 3481/4885ALDH1A1 2412/4885KDM4E 1314/4885
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF POLM, POLN, POLI LMNA 269/4885ALDH1A1 4367/4885KDM4E 4639/4885
US-20100036133-A1 NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANALYSES CHAMP1, ANXA5, ANXA3 LMNA 3830/4885ALDH1A1 3530/4885KDM4E 1701/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS LMNA 2991/4885ALDH1A1 3370/4885KDM4E 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.